331 related articles for article (PubMed ID: 35922704)
1. COVID-19 associated multisystemic mucormycosis from India: a multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome.
Sahu M; Shah M; Mallela VR; Kola VR; Boorugu HK; Punjani AAR; Kumar RV; Kumar S; Manusrut M; Kumar SCR; Rathod R; Babu DM; Gonuguntla HK; Yedlapati GK; Mallu GR; Reddy YS; Reddy VV; Alwala S; Bongu VK; Kamalesh A; Kumar RNK; Jaishetwar GS; Bagapally RS; Srinivas JS; Balasubramaniam A; Rajagopalan BK; Pullikanti B; Prakasham SP; Nimmala P; Nagaraju B; Sahoo PR;
Infection; 2023 Apr; 51(2):407-416. PubMed ID: 35922704
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
[TBL] [Abstract][Full Text] [Related]
3. Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India.
Yadav H; Sen S; Nath T; Mazumdar S; Jain A; Verma P; Gupta P
Indian J Ophthalmol; 2022 Jun; 70(6):2163-2168. PubMed ID: 35648004
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
Wasiq M; K R; Gn A
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
[TBL] [Abstract][Full Text] [Related]
6. Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India.
Vare AA; Yellambkar S; Farheen A; Nandedkar V; Bhombe SS; Shah R
Indian J Ophthalmol; 2021 Dec; 69(12):3678-3683. PubMed ID: 34827021
[TBL] [Abstract][Full Text] [Related]
7. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
Rudrabhatla PK; Reghukumar A; Thomas SV
Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
[TBL] [Abstract][Full Text] [Related]
8. Cerebrovascular Involvement in Mucormycosis in COVID-19 Pandemic.
Kulkarni R; Pujari SS; Gupta D; Ojha P; Dhamne M; Bolegave V; Dhonde P; Soni A; Adwani S; Diwan A; Duberkar D; Batra D; Deshpande R; Aurangabadkar K; Palasdeokar N
J Stroke Cerebrovasc Dis; 2022 Feb; 31(2):106231. PubMed ID: 34890962
[TBL] [Abstract][Full Text] [Related]
9. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India.
Patel A; Kaur H; Xess I; Michael JS; Savio J; Rudramurthy S; Singh R; Shastri P; Umabala P; Sardana R; Kindo A; Capoor MR; Mohan S; Muthu V; Agarwal R; Chakrabarti A
Clin Microbiol Infect; 2020 Jul; 26(7):944.e9-944.e15. PubMed ID: 31811914
[TBL] [Abstract][Full Text] [Related]
10. COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India.
Aranjani JM; Manuel A; Abdul Razack HI; Mathew ST
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009921. PubMed ID: 34793455
[TBL] [Abstract][Full Text] [Related]
11. Satellite Epidemic of Covid-19 Associated Mucormycosis in India: A Multi-Site Observational Study.
Satija A; Anand T; Mukherjee A; Velamuri PS; Singh KJ; Das M; Josten K; Keche AY; Nagarkar NM; Gupta P; Himanshu D; Mistry SN; Patel JD; Rao P; Rohatgi S; Ghosh S; Hazra A; Kindo AJ; Annamalai R; Rudramurthy SM; Singh MP; Shameem M; Fatima N; Khambholja JR; Parikh S; Madkaikar M; Pradhan VD; Bhargava A; Mehata R; Arora RD; Tigga R; Banerjee G; Sonkar V; Malhotra HS; Kumar N; Patil R; Raut CG; Bhattacharyya K; Arthur P; Somu L; Srikanth P; Shah PB; Panda NK; Sharma D; Hasan W; Ahmed A; Bathla M; Solanki S; Doshi H; Kanani Y; Patel N; Shah Z; Tembhurne AK; Rajguru C; Sankhe LR; Chavan SS; Yadav RM; Panda S
Mycopathologia; 2023 Oct; 188(5):745-753. PubMed ID: 37490256
[TBL] [Abstract][Full Text] [Related]
12. Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study.
Gandhi A; Narula A; Chandra S; Agarwal D; Mehta A; Nayak S; Arora S; Capoor MR
Int Ophthalmol; 2023 May; 43(5):1571-1580. PubMed ID: 36273362
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.
Muthu V; Rudramurthy SM; Chakrabarti A; Agarwal R
Mycopathologia; 2021 Dec; 186(6):739-754. PubMed ID: 34414555
[TBL] [Abstract][Full Text] [Related]
14. Cumulative Mortality and Factors Associated With Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India.
Choksi T; Agrawal A; Date P; Rathod D; Gharat A; Ingole A; Chaudhari B; Pawar N
JAMA Ophthalmol; 2022 Jan; 140(1):66-72. PubMed ID: 34882192
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
[TBL] [Abstract][Full Text] [Related]
16. Rhino-orbital mucormycosis: Our experiences with clinical features and management in a tertiary care center.
Singh SP; Rana J; Singh VK; Singh R; Sachan R; Singh S; Jain S
Rom J Ophthalmol; 2021; 65(4):339-353. PubMed ID: 35087975
[No Abstract] [Full Text] [Related]
17. Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.
Chavan RP; Ingole SM; Nazir HA; Desai WV; Kanchewad GS
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3201-3210. PubMed ID: 35122509
[TBL] [Abstract][Full Text] [Related]
18. A fungal epidemic amidst a viral pandemic: Risk factors for development of COVID-19 associated rhino-orbital-cerebral mucormycosis in India.
Vasanthapuram VH; Gupta R; Adulkar N; Nair AG; Bradoo RA; Hegde R; Singh U; Tadepalli S; Mukherjee B; Kamal S; Alam MS; Rao R; Ananthakrishna S; Backiavathy V; Murthy AK; D'Cunha L; Dudeja G; Joji A; Kiran A; Koka K; Goswami Mukhopadhyay M; Nisar SP; Rao PR; Shinde CA
Orbit; 2023 Feb; 42(1):30-41. PubMed ID: 35192435
[TBL] [Abstract][Full Text] [Related]
19. Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbital-cerebral mucormycosis: preserving the salvageable.
Keshri A; Mathialagan A; Aishwarya A; Ravisankar ; Bhuskute G; Kanaujia V; Singh AK; Singh RK; Dhiman RK; Agarwal R
Eur Arch Otorhinolaryngol; 2023 Feb; 280(2):819-827. PubMed ID: 36053359
[TBL] [Abstract][Full Text] [Related]
20. Mucormycosis and COVID-19: An epidemic within a pandemic in India.
Selarka L; Sharma S; Saini D; Sharma S; Batra A; Waghmare VT; Dileep P; Patel S; Shah M; Parikh T; Darji P; Patel A; Goswami G; Shah A; Shah S; Lathiya H; Shah M; Sharma P; Chopra S; Gupta A; Jain N; Khan E; Sharma VK; Sharma AK; Chan ACY; Ong JJY
Mycoses; 2021 Oct; 64(10):1253-1260. PubMed ID: 34255907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
